Kyverna Secures $150M Loan, Stock Soars as Phase 2 SPS Data Call Approaches
By ATTN Desk · Editorial oversight: Sean Han
Company Overview
Kyverna Therapeutics Inc. (NASDAQ: KYTX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Emeryville, California. The company develops chimeric antigen receptor (CAR) T-cell therapies aimed at achieving treatment-free remission in B cell-driven autoimmune diseases. Its lead autologous candidate, KYV-101 (miv-cel), is in Phase 2 registrational trials for stiff person syndrome (SPS), with additional studies in multiple sclerosis, myasthenia gravis, lupus nephritis, and systemic sclerosis. Kyverna also develops next-generation autologous and allogeneic CD19-directed cell therapies through collaborations, including a research and development agreement with Intellia Therapeutics, Inc.
Corporate Structure and Workforce
As of December 2025, Kyverna employs between 51 and 200 people across research, clinical operations, and corporate functions. The company maintains a hybrid work environment and offers a range of employee benefits, including unlimited flexible paid time off (PTO), parental leave, and equity grants. Clinical-stage operations are conducted at sites in the United States, Germany, and other regions participating in ongoing trials.
CAR T-cell therapy by Anton Darius
Recent Developments
- On November 13, 2025, Kyverna hosted a webinar on CAR T-cell therapy in generalized myasthenia gravis (gMG) to discuss the KYSA-6 Phase 3 trial enrolling patients with AChR or MuSK antibody-positive gMG.
- On November 17, 2025, CEO Warner Biddle presented at the Jefferies Global Healthcare Conference in London, providing an update on the company’s neuroimmunology program.
- In November 2025, Kyverna closed a loan facility of up to $150 million with Oxford Finance LLC to support its late-stage indications in SPS and gMG, and to accelerate pre-launch activities.
- On December 15, 2025, at 8:00 AM ET, the company will hold a conference call to review topline data from the registrational KYSA-8 Phase 2 trial of miv-cel (KYV-101) in stiff person syndrome.
- Also on December 15, 2025, Kyverna filed two Current Reports on Form 8-K with the SEC (Accession Nos. 0001193125-25-318469 and 0001193125-25-318377) outlining material corporate events and management commentary.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (Dec 15, 2025) | $12.05 |
| Day’s Change | +37.24 % |
| Trading Volume | 1,444,799 |
| Fair Value (Yahoo Finance) | $8.78 |
| Dividend Score | Low |
| Hiring Score | Low |
| Insider Sentiment Score | Not rated |
The 37.24 % gain on December 15 reflects investor response to clinical trial progress and SEC disclosures. Kyverna’s balance sheet was strengthened in November by the $150 million loan facility, providing financial support for registrational programs. The company’s product pipeline includes KYV-102 (autologous, rapid manufacturing) and KYV-201 (allogeneic) in earlier clinical stages. A November 17 Schedule 13G filing indicates that GordonMD Global Investments LP and related entities collectively hold approximately 19.4 % of outstanding shares.
Market Position and Industry Context
Kyverna operates in the area of CAR T technology applied to autoimmune diseases. By targeting CD19-expressing B cells, the company aims to reset immune responses after a single infusion. This strategy is informed by developments in treating hematologic malignancies but faces challenges including manufacturing scalability, regulatory approval processes, and market adoption by payers. Competitors in the biotechnology sector include firms developing targeted biologics and allogeneic therapies. Kyverna’s focus on indications such as SPS and gMG situates it within a market characterized by a limited number of approved therapies, while collaborations with Intellia and others aim to enhance its capabilities.
tl;dr
On December 15, 2025, Kyverna will discuss topline Phase 2 data for KYV-101 in stiff person syndrome during an 8:00 AM ET conference call. Earlier in November, the company secured a $150 million loan facility and presented at the Jefferies Global Healthcare Conference. Phase 3 enrollment for generalized myasthenia gravis continues, with additional readouts expected in early 2026.